Literature DB >> 3105445

Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats.

C Thauvin, G M Eliopoulos, S Willey, C Wennersten, R C Moellering.   

Abstract

Intermittent administration of ampicillin alone has resulted in high failure rates in previously described animal models of enterococcal endocarditis. We developed a rat model of enterococcal endocarditis which permits comparison of continuous intravenous infusion of ampicillin with intramuscular therapy. Continuous low-dose ampicillin infusion (450 mg/kg [body weight] per day) was compared with the same dose given intramuscularly in three divided doses and with high-dose infusion (4.5 g/kg per day) of the drug. For the infecting strain of Streptococcus faecalis, the MIC and MBC were 1 microgram/ml. Mean ampicillin levels in serum were 53.9 +/- 4.8 (peak) and less than 1 (trough), 8.7 +/- 1.4, and 244 +/- 29 micrograms/ml for intramuscular, low-dose, and high-dose regimens, respectively. Ampicillin infusion therapy significantly increased the survival rate and sterilization of blood cultures. Continuous infusions were superior to intermittent therapy in eradicating bacteremia. After 5 days of treatment, low-dose ampicillin infusion was more effective than intermittent therapy in sterilizing cardiac vegetations (P less than 0.01). Continuous-infusion therapy at either dose was significantly more effective than intramuscular injection in reducing bacterial titers in cardiac vegetations (5.4 +/- 1.0 log10 CFU/g [low dose], 4.8 +/- 0.3 log10 CFU/g [high dose], and 7.7 +/- 0.3 log10 CFU/g [intramuscular]). However, no statistically significant advantage was found for high-dose compared with low-dose ampicillin infusion in lowering bacterial titers in vegetations (P greater than 0.3).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105445      PMCID: PMC174678          DOI: 10.1128/AAC.31.2.139

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Bacterial endocarditis. A review of 148 cases.

Authors:  W R VOGLER; E R DORNEY; H A BRIDGES
Journal:  Am J Med       Date:  1962-06       Impact factor: 4.965

2.  Penetration of antibiotics into fibrin loci in vivo. 3. Intermittent vs. continuous infusion and the effect of probenecid.

Authors:  M Barza; J Brusch; M G Bergeron; L Weinstein
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

3.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

Review 4.  Continuous vs. intermittent administration of antimicrobial agents: tissue penetration and efficacy in vivo.

Authors:  M G Bergeron; D Beauchamp; A Poirier; A Bastille
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

5.  A microtechnique for the determination of antibiotics in muscle.

Authors:  O Cars; S Ogren
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

6.  Studies on antibiotic synergism against enterococci. I. Bacteriologic studies.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Lab Clin Med       Date:  1971-05

7.  Ampicillin in the treatment of enterococcal endocarditis.

Authors:  H N Beaty; M Turck; R G Petersdorf
Journal:  Ann Intern Med       Date:  1966-10       Impact factor: 25.391

8.  Synergism of ampicillin and gentamicin against obstructive pyelonephritis due to Escherichia coli in rats.

Authors:  M P Glauser; J M Lyons; A I Braude
Journal:  J Infect Dis       Date:  1979-02       Impact factor: 5.226

9.  Ampicillin therapy of experimental enterococcal endocarditis.

Authors:  R R Tight
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

10.  Rat model of experimental endocarditis.

Authors:  J Santoro; M E Levison
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

View more
  46 in total

1.  In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.

Authors:  H W Boucher; C Thauvin-Eliopoulos; D Loebenberg; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  Increasing Antimicrobial Resistance: Therapeutic Implications for Enterococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

4.  Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.

Authors:  J Berkhout; L G Visser; P J van den Broek; J A M van de Klundert; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 5.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 6.  Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis.

Authors:  A C Cremieux; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 7.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 8.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

9.  Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.

Authors:  William K Lau; David Mercer; Kamal M Itani; David P Nicolau; Joseph L Kuti; Debra Mansfield; Adrian Dana
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

10.  Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.

Authors:  S Daenen; Z Erjavec; D R Uges; H G De Vries-Hospers; P De Jonge; M R Halie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.